FYI: ML | Serology Topics Related to COVID-19

From: Ministerial Services / Services Ministériels (HC/SC) < hc.ministerialservices-

servicesministeriels.sc@canada.ca>

"Gaebel, Patrick (HC/SC)" <patrick.gaebel@canada.ca>, "Hoelscher, Sarah

(HC/SC)" <sarah.hoelscher@canada.ca>, "Ing, Amanda (HC/SC)"

cc: <amanda.ing@canada.ca>, "Kari, Sawssan (HC/SC)" <sawssan.kari@canada.ca>,

"Leclerc, Heather (HC/SC)" <heather.leclerc@canada.ca>, "McNaughton, Joleen

(HC/SC)" <joleen.mcnaughton@canada.ca>, "Norng, Alicia (HC/SC)"

<alicia.norng@canada.ca>, "Roussy, Alyssa (HC/SC)" <alyssa.roussy@canada.ca>

Date: Mon, 13 Jul 2020 13:24:33 +0000

Attachment

PHAC_ML_CoV_Serology Topics 2020-07-10_1734_FINAL-EN.docx (66.36 kB)

Good morning,

Please find attached media lines for your information.

Thank you, Alicia

Issue Statement: The attached document contains key messages that combines all the serology topics related to COVID-19 in one spot. Most of the key messages have been previously approved except the new NML section that is highlighted in yellow. The many aspects of serology testing are addressed in these key messages. These include: how serological tests work to detect antibodies; the role of the Immunity Taskforce; the role of the National Microbiology Laboratory (NML) in serology testing and determining how long immunity lasts; Canada's participation in the WHO Solidarity II Serological Study; and Health Canada's role in approving serological tests.

Alicia Norng

Communications Officer | Agente de communications Ministerial Services | Services ministériels Communications and Public Affairs Branch | Direction générale des affaires publiques et des communications <u>alicia.norng@canada.ca</u> | 613-297-6991

Serving the Public Health Agency of Canada and Health Canada | Au service de l'Agence de la santé publique du Canada et de Santé Canada